Midstage Vitae drug flops in PhII, leaving Allergan’s $640M buyout in question

Midstage Vitae drug flops in PhII, leaving Allergan’s $640M buyout in question badams Thu, 11/03/2016 - 07:05…
Read the full story: Feed